SOX2 and breast cancer: In contrast, in the MDA-MB-231 cell line, a highly malignant breast cancer cell line, Oxamate treatment decreased Sox2 and E-cadherin expression, while Nanog and N-cadherin expression remained unchanged (Figure 5C).